Faron Pharma Share News (FARN)
FARN Share
FARN Share
FARN Share
FARN Share
FARN
FARN Share
FARN Level 2
FARN Live
FARN Broker
FARN Directors
FARN Financial
FARN
FARN Short
FARN
Last checked at -
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and Tuesday and not separately reported by Alliance News:
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Read more
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced updated survival data from the phase 1 and 2 study investigating the safety and efficacy of 'bexmarilimab' on Wednesday.
Read moreEXECUTIVE CHANGES: Anglo Pacific promotes investment head to CEO
Read more(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced the appointment of Marie-Louise Fjällskog as its chief medical officer on Tuesday, to be based in Boston, Massachusetts and effective immediately.
Read moreFaron appoints Sensei Biotherapeutics's Marie-Louise Fjallskog as CMO
Read moreEXECUTIVE CHANGES: GCP Infrastructure picks Rothschild banker as chair
Read moreTRADING UPDATES: Shepherd Neame losses cut; Beximco to sell Covid pill
Read more(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Tuesday that the arbitration tribunal appointed by the Arbitration Institute of the Stockholm Chamber of Commerce (SCC) had ruled in its favour in its case against Rentschler Biopharma.
Read moreIN BRIEF: Faron Pharma raises EUR10.5 million in share placing
Read moreIN BRIEF: Faron Pharma to raise at least EUR8 million via placing
Read moreIN BRIEF: Faron Pharma hails updated results from Matins study
Read moreTRADING UPDATES: Glenveagh, IOG swing to profit; Faron loss widens
Read more(Sharecast News) - Clinical-stage biopharmaceuticals company Faron Pharmaceuticals announced on Wednesday that the first patient has been dosed in the phase 2 and 3 'HIBISCUS' trial, assessing 'Traumakine', or intravenous interferon beta-1a, as a first-line treatment for hospitalised Covid-19 patients.
Read moreIN BRIEF: Faron Pharmaceuticals begins study of new Covid treatment
Read more
Last checked at